AtriCure (Nasdaq:ATRC) shares took a slight hit today on second-quarter results that were mixed compared to the consensus forecast. The Mason, Ohio-based cardiac ablation device company posted losses of $14.8 million, or 32¢ per share, on sales of $84.5 million for the three months ended June 30, 2022, for a slight bottom-line gain on sales […]
AtriCure Inc.
AtriCure treats first patient in Isolator Synergy clamp trial
AtriCure (Nasdaq:ATRC) announced today that it treated the first patient in its HEAL-IST clinical trial in Belgium. Dr. Mark LaMeir and Dr. Carlo de Asmundis treated the first patient in the HEAL-IST trial evaluating the AtriCure Isolator Synergy clamp for treating drug-refractory patients diagnosed with inappropriate sinus tachycardia (IST) at University Hospital Brussels. “Symptomatic IST […]
AtriCure launches clamp for cardiac tissue ablation
AtriCure (Nasdaq:ATRC) announced today that it launched the EnCompass Clamp as part of its Isolator Synergy ablation system. Mason, Ohio-based AtriCure received FDA 510(k) clearance for the EnCompass Clamp for the ablation of cardiac tissue during cardiac surgery to make concomitant surgical ablations more efficient. According to a news release, the platform includes parallel closure, […]
These medtech companies care a lot about research
They’re making glaucoma-treating stents, tumor-treating fields, coin-sized CGMs and more. Discover the medtech companies that spend the most on research as a percentage of revenue. The list comes from our annual Big 100 report, which examines the world’s 100 largest medical device companies and ranks them by revenue. (Check out our full Big 100 report […]
AtriCure beats The Street in Q2 results
AtriCure (NSDQ:ATRC) posted second-quarter results this week that beat the overall consensus on Wall Street. The Mason, Ohio-based company reported losses of -$16.3 million, or -36¢ per share, on sales of $71.4 million for the three months ended June 30 for a sales growth of 74.84% compared with Q2 2020. Adjusted to exclude one-time items, earnings […]
AtriCure AFib treatment device wins FDA approval
AtriCure (NSDQ:ATRC) announced today that the FDA approved its EPi-Sense system for treating long-standing persistent atrial fibrillation (Afib). Mason, Ohio-based AtriCure’s EPi-Sense system demonstrated superiority in the Hybrid AF therapy arm compared to endocardial catheter ablation alone in the Converge clinical trial, according to a news release. AtriCure’s Hybrid AF therapy is a minimally invasive […]
AtriCure names Angie Wirick as chief financial officer
AtriCure (NASDAQ:ATRC) recently announced that it has appointed Angie Wirick as chief financial officer, effective August 6. Wirick, who was VP of finance, replaces Andy Wade who is stepping down for personal reasons and will continue to serve in an advisory role through March 5, 2021. “On behalf of our team at AtriCure and our Board […]
AtriCure to raise $100m from public offering
AtriCure (NASDAQ:ATRC) said today that it commenced a public offering to issue and sell roughly $100 million worth of its common stock. The Mason, Ohio–based company — maker of treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management — said it plans to grant the underwriters of the offering a 30-day option to […]
These 10 medtech companies care a lot about research
These 10 medical device companies spent the largest portion of their budgets on research and development. Here’s a look at what they produced. Each year, Medical Design & Outsourcing compiles a list of the top 100 medical device companies across the globe and ranks the companies based on annual revenue for the most recent fiscal year. We […]
AtriCure wins expanded indications for AtriClip LAA
AtriCure (NSDQ:ATRC) said today that it won expanded 510(k) clearances from the FDA for its AtriClip left atrial appendage device. The new indications cover a change from occlusion of the LAA to exclusion and adding electrical isolation as a claim, Mason, Ohio-based AtriCure said. AtriClip excludes the LAA and causes its tissue to die from loss […]
AtriCure closes $300m SentreHeart buyout
AtriCure (NSDQ:ATRC) said yesterday that it closed the $300 million buyout of SentreHeart and its Lariat left atrial appendage closure device. The offer included $40 million in up-front cash and stock, plus $140 million in clinical and regulatory milestones and $120 million in reimbursement milestones, all payable in cash and stock, Mason, Ohio-based AtriCure said when the […]
